ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT07590531

AMT-116 in Combination With Ivosidan in Patients With Lung Cancer

An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivosimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor

Multitude Therapeutics Inc.

Enrollment

118 participants

Start Date

Jun 29, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)

Summary

The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AK112 and a drug called AMT-116 for people with advanced non small cell lung cancer (nsclc). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAMT-116

AMT-116 is an antibody Drug Conjugate (ADC)

DRUGAK112

AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug

Locations(2)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Zhejiang cancer hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07590531

Related Trials

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NCT076697791 location

Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway

NCT076496291 location

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

NCT072592261 location

Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors

NCT067735071 location

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

NCT067288521 location